MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/28/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. ULTA
8. NVDA
9. GAP
10. DG

Go back to MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
(NASDAQ: MBX) Delayed: 63.00 -3.39 (5.11%)
Previous Close $66.39    52 Week High $ 
Open $66.14    52 Week Low $ 
Day High $66.14    P/E N/A 
Day Low $62.99    EPS $ 
Volume 307,646